Search

Your search keyword '"Schellens, J H M"' showing total 949 results
Start Over Author "Schellens, J H M"
949 results on '"Schellens, J H M"'

3. Geneesmiddelen

Author

Cohen, A. F., Danhof, M., de Greef, H. J. M. M., Ijzerman, A. P., Kenter, M. J. H., Schellens, J. H. M., Sitsen, J. M. A., Cohen, A. F., editor, Danhof, M., editor, de Greef, H. J. M. M., editor, Ijzerman, A. P., editor, Kenter, M. J. H., editor, Schellens, J. H. M., editor, and Sitsen, J. M. A., editor

Published
2017
Full Text
View/download PDF

4. Maligne aandoeningen

Author

van Rijswijk, R. E. N., Schellens, J. H. M., Vermorken, J. B., van der Vijgh, W. J. F., Cohen, A. F., editor, Danhof, M., editor, de Greef, H. J. M. M., editor, Ijzerman, A. P., editor, Kenter, M. J. H., editor, Schellens, J. H. M., editor, and Sitsen, J. M. A., editor

Published
2017
Full Text
View/download PDF

23. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Author

Omlin, A., Jones, R. J., van der Noll, R., Satoh, T., Niwakawa, M., Smith, S. A., Graham, J., Ong, M., Finkelman, R. D., Schellens, J. H. M., Zivi, A., Crespo, M., Riisnaes, R., Nava-Rodrigues, D., Malone, M. D., Dive, C., Sloane, R., Moore, D., Alumkal, J. J., Dymond, A., Dickinson, P. A., Ranson, M., Clack, G., de Bono, J., and Elliott, T.

Published
2015
Full Text
View/download PDF

28. Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Author

Verheijen, R B, Thijssen, B, Atrafi, F, Schellens, J H M, Rosing, H, de Vries, N, Beijnen, J H, Mathijssen, R H J, Steeghs, N, Huitema, A D R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, and Medical Oncology

Subjects
Bioanalysis, Clinical Biochemistry, Hematocrit, 030226 pharmacology & pharmacy, 01 natural sciences, Biochemistry, Sensitivity and Specificity, Tandem Mass Spectrometry/methods, Analytical Chemistry, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Drug Stability, Liquid chromatography–mass spectrometry, Tandem Mass Spectrometry, Journal Article, medicine, Everolimus/blood, Humans, Everolimus, Whole blood, Chromatography, medicine.diagnostic_test, Chemistry, 010401 analytical chemistry, Chromatography, Liquid/methods, Reproducibility of Results, Cell Biology, General Medicine, 0104 chemical sciences, Dried blood spot, Therapeutic drug monitoring, Liquid/methods, Linear Models, Drug Monitoring, medicine.drug, Chromatography, Liquid
Abstract

Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of various tumor types. Less invasive measurement of everolimus concentrations could facilitate pharmacokinetic studies and personalized dosing based on whole blood concentrations, known as therapeutic drug monitoring. Volumetric Absorptive Microsampling (VAMS) has been introduced as a patient friendly, less invasive sampling technique to obtain an accurate volume of whole blood regardless of hematocrit value. We describe the bioanalytical validation and clinical application of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to quantify everolimus using VAMS. For the quantification, 13C2D4-Everolimus was used as internal standard (IS). Everolimus and the IS were extracted with methanol from the VAMS device, which was evaporated after ultrasonification and shaking. The residue was reconstituted in 20 mM ammonium formate buffer and methanol (50%, v/v) of which 5 μL was injected into the LC-MS/MS system. Quantification was performed for the ammonium adduct of everolimus in positive electrospray ion mode. The VAMS method met all pre-defined validation criteria. Accuracy and precision were within 11.1% and ≤14.6%, respectively. Samples were shown to be stable on the VAMS device for at least 362 days at ambient temperatures. Considerable biases from −20 to 31% were observed over a 30–50% hematocrit range. Although the method fulfilled all validation criteria, the perceived advantage of VAMS over dried blood spot sampling could not be demonstrated. Despite the effect of hematocrit, using an empirically derived formula the whole blood everolimus concentration could be back calculated with reasonable accuracy in the clinical application study.

Published
2019

34. Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy

Author

Zorgeenheid Heelkunde Medisch, MS CGO, Trialsecretariaat Medische Oncologie, Apotheek Onderzoek, Cancer, Koemans, W J, van der Kaaij, R T, Wassenaar, E C E, Grootscholten, C, Boot, H, Boerma, D, Los, M, Imhof, O, Schellens, J H M, Rosing, H, Huitema, A D R, van Sandick, J W, Zorgeenheid Heelkunde Medisch, MS CGO, Trialsecretariaat Medische Oncologie, Apotheek Onderzoek, Cancer, Koemans, W J, van der Kaaij, R T, Wassenaar, E C E, Grootscholten, C, Boot, H, Boerma, D, Los, M, Imhof, O, Schellens, J H M, Rosing, H, Huitema, A D R, and van Sandick, J W

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results